1 week Ago By ABMN Staff
American Century Companies Inc. lifted its position in ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD – Free Report ) by 55.
2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 141,265 shares of the biopharmaceutical company’s stock after buying an additional 50,238 shares during the quarter. American Century Companies Inc.
’s holdings in ACADIA Pharmaceuticals were worth $2,592,000 as of its most recent SEC filing. Other institutional investors have also added to or reduced their stakes in the company. SG Americas Securities LLC lifted its stake in ACADIA Pharmaceuticals by 380.
3% in the fourth quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company’s stock valued at $45,576,000 after acquiring an additional 1,966,607 shares during the last quarter. Barclays PLC increased its stake in shares of ACADIA Pharmaceuticals by 126.
2% during the 3rd quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company’s stock worth $4,269,000 after purchasing an additional 154,854 shares during the last quarter. Burney Co.
bought a new stake in shares of ACADIA Pharmaceuticals in the 4th quarter valued at about $6,953,000. Proficio Capital Partners LLC acquired a new stake in ACADIA Pharmaceuticals in the 4th quarter valued at about $272,000. Finally, State Street Corp grew its holdings in ACADIA Pharmaceuticals by 3.
0% during the third quarter. State Street Corp now owns 5,973,874 shares of the biopharmaceutical company’s stock worth $91,878,000 after purchasing an additional 173,084 shares during the period. 96.
71% of the stock is currently owned by institutional investors and hedge funds. Insider Buying and Selling In other news, Director Elizabeth A. Garofalo sold 4,919 shares of the company’s stock in a transaction on Wednesday, March 5th.
The stock was sold at an average price of $18.23, for a total transaction of $89,673.37.
Following the completion of the sale, the director now directly owns 17,595 shares in the company, valued at approximately $320,756.85. This represents a 21.
85 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink . Also, EVP Mark C.
Schneyer sold 3,171 shares of the stock in a transaction on Wednesday, March 26th. The stock was sold at an average price of $17.05, for a total value of $54,065.
55. Following the sale, the executive vice president now directly owns 56,889 shares in the company, valued at approximately $969,957.45.
This trade represents a 5.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here .
Insiders have sold 10,433 shares of company stock valued at $187,319 over the last 90 days. 28.30% of the stock is owned by corporate insiders.
ACADIA Pharmaceuticals Trading Down 5.0 % Wall Street Analyst Weigh In A number of analysts have recently issued reports on ACAD shares. Morgan Stanley reaffirmed an “equal weight” rating and issued a $20.
00 price objective on shares of ACADIA Pharmaceuticals in a research report on Friday, March 7th. Guggenheim cut ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the company from $23.00 to $20.
00 in a research note on Friday, January 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th.
HC Wainwright reiterated a “buy” rating and issued a $27.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. Finally, StockNews.
com upgraded shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 8th. Eight investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.
com, the company has an average rating of “Moderate Buy” and an average target price of $23.93. Get Our Latest Stock Analysis on ACAD ACADIA Pharmaceuticals Company Profile ( Free Report ) ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States.
The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. Further Reading Want to see what other hedge funds are holding ACAD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ACADIA Pharmaceuticals Inc.
( NASDAQ:ACAD – Free Report ). Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
